Drug profile

The FDA adverse-event record for Torbutrol

19 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Torbutrol. See the species affected, top reactions, and outcomes below.

19
adverse-event reports
5.3%
death-coded share
Dog
most-reported species
5
Vomiting - top reaction
Verify with FDA CVM →
Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
19
Total Reports
1
Deaths Reported
5.3%
Death Rate

Active Ingredients

Torbutrol

Administration Routes

UnknownIntramuscularIntravenous

Species Affected

Dog 18
Cat 1

Most Affected Breeds

Retriever - Labrador 2
Pointing Dog - Hungarian Short-haired (Vizsla) 2
Doberman Pinscher 2
Pekingese 1
Dachshund - Standard Smooth-haired 1
Rottweiler 1
Shih Tzu 1
Domestic Shorthair 1
Dog (unknown) 1
Schnauzer - Miniature 1

Most Reported Reactions

Vomiting 5
Lack of efficacy (endoparasite) - heartworm 4
Weight loss 3
Elevated alanine aminotransferase (ALT) 3
Diarrhoea 3
Injection site reddening 2
Injection site weeping (see also 'skin') 2
Injection site scab 2
Elevated serum alkaline phosphatase (SAP) 2
Proteinuria 2
Haematuria 2
Inappetence 2

Outcome Breakdown

Outcome Unknown
8 (42.1%)
Ongoing
6 (31.6%)
Recovered/Normal
3 (15.8%)
Died
1 (5.3%)
Recovered with Sequela
1 (5.3%)

Torbutrol Adverse Event Insights

19 reports name Torbutrol; 1 recorded a death outcome (5.3% of reported events, not a population-level mortality rate). Active ingredient: Torbutrol. Administration routes: Unknown, Intramuscular, Intravenous.

By species: Dog (18 reports), Cat (1 reports). By breed: Retriever - Labrador (2), Pointing Dog - Hungarian Short-haired (Vizsla) (2), Doberman Pinscher (2).

Leading clinical signs: Vomiting (5), Lack of efficacy (endoparasite) - heartworm (4), Weight loss (3), Elevated alanine aminotransferase (ALT) (3). Outcome, 19 coded reports: Outcome Unknown leads at 42.1%.

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

Every figure on PlainBreed is rendered directly from FDA openFDA adverse event data, no number is typed in by an editor. This page draws directly on FDA openFDA data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.